Who are Hydromorphone HCI OROS's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Methadone Maintenance Therapy, Intra thecal morphine., Zaldiar®, gabapentin + tramadol, Controlled Release Morphine, Morphine Retard.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hydromorphone-hci-oros.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Hydromorphone HCI OROS — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hydromorphone HCI OROS (Hydromorphone HCI OROS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic. Area: Pain management.

phase 2 Opioid analgesic μ-opioid receptor Pain management Small molecule Live · refreshed every 30 min

Target snapshot

Hydromorphone HCI OROS (Hydromorphone HCI OROS) — Janssen Korea, Ltd., Korea. μ-opioid receptor agonist

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Hydromorphone HCI OROS TARGET	Hydromorphone HCI OROS	Janssen Korea, Ltd., Korea	phase 2	Opioid analgesic	μ-opioid receptor
Methadone Maintenance Therapy	Methadone Maintenance Therapy	Oregon Health and Science University	marketed	Synthetic opioid agonist	Mu opioid receptor (μ-opioid receptor)
Intra thecal morphine.	Intra thecal morphine.	Ain Shams University	marketed	Opioid agonist	Mu opioid receptor (μ-opioid receptor)
Zaldiar®	Zaldiar®	Labopharm Inc.	marketed	Opioid analgesic combination	μ-opioid receptor; norepinephrine and serotonin transporters; COX (paracetamol component)
gabapentin + tramadol	gabapentin + tramadol	Southwest Hospital, China	marketed	Analgesic combination (anticonvulsant + opioid)	Voltage-gated calcium channels (Cav2.1, Cav2.2); μ-opioid receptor; serotonin and norepinephrine transporters
Controlled Release Morphine	Controlled Release Morphine	Nova Scotia Health Authority	marketed	Opioid analgesic	Mu-opioid receptor (μ-opioid receptor)
Morphine Retard	Morphine Retard	Huib A.M. Kerstjens	marketed	Opioid analgesic	Mu-opioid receptor (μ-opioid receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic class)

Alza Corporation, DE, USA · 3 drugs in this class
Labopharm Inc. · 3 drugs in this class
University of Rochester · 3 drugs in this class
Purdue Pharma LP · 3 drugs in this class
Institute of Child Health · 2 drugs in this class
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · 2 drugs in this class
Fujian Cancer Hospital · 2 drugs in this class
Children's Hospital of Fudan University · 2 drugs in this class
AdventHealth · 2 drugs in this class
Danish University of Pharmaceutical Sciences · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hydromorphone HCI OROS — Competitive Intelligence Brief. https://druglandscape.com/ci/hydromorphone-hci-oros. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab